1. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J
Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7. PMID:
32943087; PMCID: PMC7499842.
2. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen
(BCMA) in multiple myeloma: rationale for targeting and current therapeutic
approaches. Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z.
Epub 2020 Feb 13. PMID: 32055000; PMCID: PMC7214244.
3. Yang J, Zhou W, Li D, Niu T, Wang W. BCMA-targeting chimeric antigen receptorT-cell therapy for multiple myeloma. Cancer Lett. 2023 Jan 28;553:215949. doi:10.1016/j.canlet.2022.215949. Epub 2022 Oct 8. PMID: 36216149.
4. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C,
Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ,
Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F.
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun.2024 Jan 19;15(1):615. doi: 10.1038/s41467-024-44873-4. PMID: 38242888; PMCID:PMC10798961.